Arecor Therapeutics (AREC)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

140.00p
   
  • Change Today:
      2.50p
  • 52 Week High: 270.00
  • 52 Week Low: 132.50
  • Currency: UK Pounds
  • Shares Issued: 30.63m
  • Volume: 23,983
  • Market Cap: £42.88m

Expectations exceeded for Arecor's two lead clinical-stage programmes

By Josh White

Date: Monday 23 May 2022

LONDON (ShareCast) - (Sharecast News) - Biopharmaceutical developer Arecor Therapeutics said in an update on Monday that it was making "huge strides" on its growth trajectory, focussed on its two lead clinical-stage programmes.
The AIM-traded firm, which was holding its annual general meeting, said the impact that the growing global number of diabetes patients was having on resources, the health sector and lives was growing.

Non-executive chair Andrew Richards said the phase 1 clinical trial data for both its lead product, the ultra-rapid insulin 'AT247', and for its second product, the concentrated rapid insulin 'AT278' targeting patients that require higher volumes of insulin, exceeded its expectations.

"We believe that our products will provide that key to unlock the future treatment landscape for diabetes," Richards told shareholders.

"With our partnered portfolio continuing to attractive high calibre pharmaceutical companies and strong support from our shareholders following our successful initial public offering on the London Stock Exchange last year, we believe that Arecor is well positioned to both deliver on existing programmes and attract new and exciting opportunities in the coming year to create long-term shareholder value."

At 1114 BST, shares in Arecor Therapeutics were up 3.16% at 392p.

Reporting by Josh White at Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

AREC Market Data

Currency UK Pounds
Share Price 140.00p
Change Today 2.50p
% Change 1.82 %
52 Week High 270.00
52 Week Low 132.50
Volume 23,983
Shares Issued 30.63m
Market Cap £42.88m

AREC Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
44.58% below the market average44.58% below the market average44.58% below the market average44.58% below the market average44.58% below the market average
25.93% above the sector average25.93% above the sector average25.93% above the sector average25.93% above the sector average25.93% above the sector average
Price Trend
73.14% below the market average73.14% below the market average73.14% below the market average73.14% below the market average73.14% below the market average
15.79% below the sector average15.79% below the sector average15.79% below the sector average15.79% below the sector average15.79% below the sector average
Income Not Available
Growth
32.96% above the market average32.96% above the market average32.96% above the market average32.96% above the market average32.96% above the market average
56.76% above the sector average56.76% above the sector average56.76% above the sector average56.76% above the sector average56.76% above the sector average

AREC Dividends

No dividends found

Trades for 28-Mar-2024

Time Volume / Share Price
16:25 228 @ 135.00p
16:14 1,800 @ 135.00p
15:17 225 @ 139.00p
14:24 230 @ 139.00p
11:19 10,000 @ 137.00p

AREC Key Personnel

CEO Sarah Jennifer Howell
CFO Susan Lowther

Top of Page